Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4′F-DMA, a new benzothiophene selective estrogen receptor modulator

Chemical Research in Toxicology

Volumn 19, Issue 6, 2006, Pages 779-787

  Liu, Hong ^a   Bolton, Judy L ^a   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ARZOXIFENE; BENZOTHIOPHENE DERIVATIVE; ESTRADIOL; FLUORINE DERIVATIVE; FULVESTRANT; GLUCURONIDE; GLUTATHIONE; NORARZOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULFATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN CACO 2; CELL STRAIN MCF 7; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA DAMAGE; DRUG ACTIVITY; DRUG CONJUGATION; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INDUCTION; EVALUATION AND FOLLOW UP; HUMAN; HUMAN CELL; LIGAND BINDING; LIVER CELL; LIVER MICROSOME; NONHUMAN; RAT; REACTION ANALYSIS; SMALL INTESTINE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TIME;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DNA DAMAGE; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; GENES, REPORTER; HUMANS; INTESTINE, SMALL; MICROSOMES; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PIPERIDINES; RATS; THIOPHENES;

EID: 33745314986     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050326r     Document Type: Article

References (50)

1. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., and Ockene, J. (2002)-Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. J. Am. Med. Assoc. 288, 321-333.
2. Beral, V. (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427.
3. Cosman, F., and Lindsay, R. (1999) Selective estrogen receptor modulators: Clinical spectrum. Endocr. Rev. 20, 418-434.
4. Conzen, S. D. (2003) Current status of selective estrogen receptor medulators (SERMs). Cancer J. 9, 4-11.
5. Shang, Y., and Brown, M. (2002) Molecular determinants for the tissue specificity of SERMs. Science 295, 2465-2468.
6. Osborne, C. K., Zhao, H., and Fuqua, S. A. (2000) Selective estrogen receptor modulators: Structure, function, and clinical use. J. Clin. Oncol. 18, 3172-3186.
7. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., Draper, M., and Christiansen, C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647.
8. Kelminski, A. (2002) The study of tamoxifen and raloxifene (STAR trial) for the prevention of breast cancer. Hawaii Med. J. 61, 209-210.
9. Riggs, B. L., and Hartmann, L. C. (2003) Selective estrogen-receptor modulators-Mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618-629.
10. Gennari, L. (2005) Lasofoxifene (Pfizer). Curr. Opin. Invest. Drugs 6, 1067-1078.
11. Yager, J. D., and Liehr, J. G. (1996) Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36, 203-232.
12. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology. Chem. Res. Toxicol. 13, 135-160.
13. Liehr, J. G. (1984) Modulation of estrogen-induced carcinogenesis by chemical modifications. Arch. Toxicol. 55, 119-122.
14. Liehr, J. G. (1983) 2-Fluoroestradiol. Separation of estrogenicity from carcinogenicity. Mol. Pharmacol. 23, 278-281.
15. Zhang, F., Chen, Y., Pisha E., Shen, L., Xiong, Y., van Breemen, R. B., and Bolton, J. L. (1999) The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem. Res. Toxicol. 12, 204-213.
16. Zhang, F., Fan, P. W., Liu, X., Shen, L., van Breeman, R. B., and Bolton, J. L. (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-Dihydroxytamoxifen-o-quinone. Chem. Res. Toxicol. 13, 53-62.
17. Shibutani, S., Ravindernath, Á., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461 -1467.
18. King, C. M. (1995) Tamoxifen and the induction of cancer. Carcinogenesis 16, 1449-1454.
19. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., Schouten, L. J., Damhuis, R. A., Bontenbal, M., and Diepenhorst, F. W., et al. (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343, 448-452.
20. Fornander, T., Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Silfversward, C., Skoog, L., Somell, A., Theve, T., and Wilking, N., et al. (1989) Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1, 117-120.
21. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
22. Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., and Cronin, W. M. (1994) Endometrial cancer in tamoxifentreated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86, 527-537.
23. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., and Kaltenberg, O. P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
24. Bolton, J. L., Yu, L., Thatcher, G. R. J. (2004) Quinoids formed from estrogens and antiestrogens. Methods Enzymol. 378, 110-123.
25. Toader, V., Xu, X., Nicolescu, A., Yu, L., Bolton, J. L., Thatcher, G. R. (2003) Nitrosation, nitration, and autoxidation of the selective estrogen receptor modulator raloxifene by nitric oxide, peroxynitrite, and reactive nitrogen/oxygen species. Chem. Res. Toxicol. 16, 1264-1276.
26. Yu, L., Liu, H., Li, W., Zhang, F., Luckie, C., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2004) Oxidation of raloxifene to quinoids: Potential toxic pathways via a diquinone methide and oquinones. Chem. Res. Toxicol. 17, 879-888.
27. Liu, H., Liu, J., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2005) Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4′-Fluoro substitution prevents quinoid formation. Chem. Res. Toxicol. 18, 162-173.
28. Liu, J., Liu, H., van Breemen, R. B., Thatcher, G. R., and Bolton, J. L. (2005) Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem. Res. Toxicol. 18, 174-182.
29. Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., Blizzard, T. A., Hammond, M. L., Stearns, R. A., Evans, D. C., Baillie, T. A., and Tang, W. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914.
30. Liu, J., Li, Q., Yang, X., van Breemen, R. B., Bolton, J. L., Thatcher, G. R. J. (2005) Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study. Chem. Res. Toxicol. 18, 1485-1496.
31. Snyder, K. R., Sparano, N., and Malinowski, J. M. (2000) Raloxifene hydrochloride. Am. J. Health Syst. Pharm. 57, 1669-1675; quiz 1676-1668.
32. Fairbairn, D. W., Olive, P. L., O'Neill, K. L. (1995) The comet assay: a comprehensive review. Mutat. Res. 339, 37-59.
33. Takemura, H., Urasaki, Y., Yoshida, A., Fukushima, T., and Ueda, T. (2001) Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells. Cancer Res. 61, 172-177.
34. Labarca, C., and Paigen, K. (1980) A simple, rapid, and sensitive DNA assay procedure. Anal. Biochem. 102, 344-352.
35. Hochner-Celnikier, D. (1999) Pharmacokinetics of raloxifene and its clinical application. Eur. J. Obstet. Gynecol. Reprod. Biol. 85, 23-29.
36. Horwitz, K. B., Costlow, M. E., and McGuire, W. L. (1975) MCF-7; A human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26, 785-795.
37. Albert, J. L., Sundstrom, S. A., and Lyttle, C. R. (1990) Estrogen regulation of placental alkaline phosphatase gene expression in a human endometrial adenocarcinoma cell line. Cancer Res. 50, 3306-3310.
38. Kemp, D. C., Fan, P. W., and Stevens, J. C. (2002) Characterization of raloxifene glucuronidation in vitro: Contribution of intestinal metabolism to presystemic clearance. Drug Metab. Dispos. 30, 694-700.
39. Sato, M., Turner, C. H., Wang, T., Adrian, M. D., Rowley, E., and Bryant, H. U. (1998) LY353381.HC1: A novel raloxifene analogue with improved SERM potency and efficacy in vivo. J. Pharmacol. Exp. Ther. 287, 1-7.
40. Buzdar, A., O'Shaughnessy, J. A., Booser, D. J., Pippen, J. E., Jr., Jones, S. E., Munster, P. N., Peterson, P., Melemed, A. S., Winer, E., and Hudis, C. (2003) Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 21, 1007-1014.
41. Raynaud, J. P., Bouton, M. M., Gallet-Bourquin, D., Philibert, D., Tournemine, C., and Azadian-Baulanger, G. (1973) Comparative study of estrogen action. Mol Pharmacol. 9, 520-533.
42. Dutertre, M., and Smith, C. L. (2000) Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J. Pharmacol. Exp. Ther. 295, 431-437.
43. Lonard, D. M., and Smith, C. L. (2002) Molecular perspectives on selective estrogen receptor modulators (SERMs): Progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67, 15-24.
44. Morgan, P., Maggs, J. L., Bulman-Page, P. C., Hussain, F., and Park, B. K. (1992) The metabolism of 2- and 4-fluoro-17 beta-oestradiol in the rat and its implications for oestrogen carcinogenesis. Biochem. Pharmacol. 43, 985-993.
45. Liehr, J. G., Fang, W. F., Sirbasku, D. A., and Ari-Ulubelen, A. (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J. Steroid Biochem. 24, 353-356.
46. Li, J. J., Purdy, R. H., Appelman, E. H., Klicka, J. K., and Li, S. A. (1985) Catechol formation of fluoro- and bromo-substituted estradiols by hamster liver microsomes. Evidence for dehalogenation. Mol. Pharmacol. 27, 559-565.
47. Ashburn, S. P., Han, X., and Liehr, J. G. (1993) Microsomal hydroxylation of 2- and 4-fluoroestradiol to catechol metabolites and their conversion to methyl ethers: Catechol estrogens as possible mediators of hormonal carcinogenesis. Mol. Pharmacol. 43, 534-541.
48. Stalford, A. C., Maggs, J. L., Gilchrist, T. L., and Park, B. K. (1994) Catecholestrogens as mediators of carcinogenesis: Correlation of aromatic hydroxylation of estradiol and its fluorinated analogues with tumor induction in Syrian hamsters. Mol. Pharmacol. 45, 1268-1272.
49. Morgan, P., Maggs, J. L., Page, P. C. B., Hussain, F., and Park, B. K. (1992) The metabolism of 2- and 4-fluoro-17b-estradiol in the rat and its implications for estrogen carcinogenesis. Biochem. Pharmacol. 43, 985-994.
50. Liu, X., Zhang, F., Liu, H., Burdette, J. E., Li, Y., Overk, C. R., Pisha, E., Yao, J., van Breemen, R. B., Swanson, S. M., and Bolton, J. L. (2003) Effect of halogenated substituents on the metabolism and estrogenic effects of the equine estrogen, equilenin. Chem. Res. Toxicol. 16, 741-749.